Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.1% Today

What is Amylyx Pharmaceuticals?

A pharmaceutical company called Amylyx Pharmaceuticals, Inc. (AMLX) is focused on developing treatments for rare neurodegenerative disorders and other medical conditions. It has gained attention from investors and analysts due to its active involvement in clinical trials.

Why is Amylyx Pharmaceuticals going down?

AMLX stock is down 5.1% on May 18, 2026 18:20

• A bearish movement in AMLX stock today may be due to profit-taking by investors following a recent bullish trend.
• The positive announcement of Phase 2 trial results for AMX0035 in Wolfram syndrome might have already been factored into the stock price, resulting in limited upward momentum.
• Despite receiving a Buy recommendation from B of A Securities, it might not have been sufficient to override broader market sentiments or short-term trading strategies.
• Speculation surrounding the Phase 3 trial outcome for AVEXITIDE and a potential launch in 2027 could be fueling speculative actions, causing some investors to sell off their positions in the near term.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Number of shareholders of Amylyx Pharmaceuticals, Inc. – BOATS:AMLX

This article from TradingView provides a financial overview of Amylyx Pharmaceuticals, Inc. (AMLX), specifically focusing on the number of shareholders. It indicates that the market is closed with no trades, and the content is primarily a listing of data sources and corporate information for TradingView. The explicit data for shareholders is not present in the body, which implies it would be presented in a table or dynamic element on the webpage.

https://www.tradingview.com/symbols/BOATS-AMLX/financials-statistics-and-ratios/number-of-shareholders/

Perceptive group holds 8.28M shares of Amylyx (AMLX) in Schedule 13G/A

Perceptive Life Sciences Master Fund, Ltd. has filed an amended Schedule 13G/A, reporting a 7.5% passive stake in Amylyx Pharmaceuticals (AMLX). The filing indicates that the Master Fund, along with Perceptive Advisors LLC and Joseph Edelman, collectively holds 8,284,882 shares of Common Stock. This ownership represents 7.5% of the 111,186,317 shares outstanding as of April 27, 2026.

https://www.stocktitan.net/sec-filings/AMLX/schedule-13g-a-amylyx-pharmaceuticals-inc-amended-passive-investment--50fe2f8a4964.html

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

Amylyx Pharmaceuticals announced the peer-reviewed publication of Week 24 and Week 48 results from its Phase 2 open-label HELIOS clinical trial of AMX0035 for Wolfram syndrome in The Journal of Clinical Investigation. The data reinforced observed stabilization or improvement in pancreatic beta cell function, glycemic control, vision, and overall symptom burden, with AMX0035 being generally well-tolerated. The company continues to collaborate with the FDA for a Phase 3 trial in Wolfram syndrome, a rare neurodegenerative disorder with no approved disease-modifying treatments.

https://www.businesswire.com/news/home/20260514300018/en/Amylyx-Pharmaceuticals-Announces-Peer-Reviewed-Publication-of-Phase-2-Open-Label-HELIOS-Trial-Data-for-AMX0035-in-The-Journal-of-Clinical-Investigation

B of A Securities Maintains Amylyx Pharmaceuticals (AMLX) Buy Recommendation

B of A Securities has reiterated its Buy rating on Amylyx Pharmaceuticals (AMLX). This indicates a continued positive outlook from the firm regarding the company's stock performance. Investors will likely view this as a signal of confidence in Amylyx's future prospects.

https://www.msn.com/en-us/money/markets/b-of-a-securities-maintains-amylyx-pharmaceuticals-amlx-buy-recommendation/ar-AA1NPZQc?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus

Amylyx Pharmaceuticals (NASDAQ: AMLX) is anticipating the Phase 3 LUCIDITY trial readout for its lead asset, AVEXITIDE, which treats post-bariatric hypoglycemia (PBH), in the third quarter. Co-CEO Joshua Cohen highlighted the trial's design to replicate earlier successful studies and its focus on an underserved patient population with no approved therapies. If positive, Amylyx plans a rapid New Drug Application submission, aiming for a 2027 launch, supported by its Breakthrough Therapy designation and strong financial position.

https://www.inkl.com/news/amylyx-pharmaceuticals-eyes-phase-3-avexitide-readout-as-2027-launch-comes-into-focus

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.1% Today

Upwork Inc. ($UPWK) Stock Forecast: Up 5.3% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Up 5.5% Today

D.R. Horton Inc. ($DHI) Stock Forecast: Up 5.1% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.5% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Up 5.9% Today

CleanSpark Inc ($CLSK) Stock Forecast: Up 7.5% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Up 5.0% Today

Etsy Inc. ($ETSY) Stock Forecast: Up 5.9% Today

Amylyx Pharmaceuticals Price History

07.03.2026 - AMLX Stock was up 5.0%

• AMLX shares surged by 6.66% on April 6, driven by positive investor sentiment and analyst recommendations pointing towards a potential upside.
• The 7.8% drop following the earnings report showing $0 revenue and concerns over stock dilution from a shelf filing led to a brief decline in the stock price.
• The completion of enrollment and dosing for the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia is a crucial milestone for AMLX, with the outcome expected to shape the company's future revenue prospects and investment narrative.
• Overall, the bullish movement today can be attributed to a mix of positive analyst outlook, milestone achievements in clinical trials, and short-term market reactions to earnings and dilution concerns.

18.04.2026 - AMLX Stock was down 5.1%

• A bearish movement in AMLX stock today may be due to profit-taking by investors following a recent bullish trend.
• The positive announcement of Phase 2 trial results for AMX0035 in Wolfram syndrome might have already been factored into the stock price, resulting in limited upward momentum.
• Despite receiving a Buy recommendation from B of A Securities, it might not have been sufficient to override broader market sentiments or short-term trading strategies.
• Speculation surrounding the Phase 3 trial outcome for AVEXITIDE and a potential launch in 2027 could be fueling speculative actions, causing some investors to sell off their positions in the near term.

15.04.2026 - AMLX Stock was down 5.6%

• The upcoming Phase 3 AVEXITIDE trial results in the third quarter failed to offset the negative impact of Amylyx Pharmaceuticals' Q1 2026 earnings miss, resulting in a significant drop in the stock price.
• Despite the favorable prospects for AVEXITIDE and the company's robust financial standing, the earnings miss brought forth investor worries regarding the current financial performance.
• Differing viewpoints on the valuation of Amylyx Pharmaceuticals emerged, as a DCF analysis suggested undervaluation while the P/B ratio indicated overvaluation, likely playing a role in the bearish market behavior as investors reevaluate the stock's true value.
• The substantial valuation discrepancy between the stock price and analyst predictions, notwithstanding the positive advancements with AVEXITIDE and strategic investments in R&D, might have intensified the downward momentum on AMLX shares.

29.03.2026 - AMLX Stock was down 5.1%

• The downward movement in AMLX stock today might be due to profit-taking by investors following several price target upgrades by different financial institutions. It is possible that traders decided to sell to secure profits after positive changes were made to the price targets.
• Despite the positive outlook from analysts and the excitement surrounding the Phase 3 LUCIDITY study data for avexitide, the market response today could indicate a short-term decline in the stock price.
• The reduction in the Co-CEO and Director's 2025 compensation compared to the previous year may also play a role in the negative sentiment towards the stock, potentially raising concerns about internal stability or performance expectations within the company.

28.03.2026 - AMLX Stock was down 5.2%

• The bearish movement in AMLX stock today could be attributed to the significant decrease in compensation for both Co-CEOs and Directors, Justin Klee and Joshua Cohen, as revealed in the recent SEC DEF14A filings. This unexpected decrease in executive pay may have raised concerns among investors about the company's financial performance or future prospects.
• Investors might be reacting to the upcoming Q3 2025 earnings preview, anticipating potentially disappointing financial results. The market sentiment could be influenced by expectations set by analysts and insiders' activities.
• Insider trading activities, hedge fund movements, and analyst ratings could have also contributed to the negative market sentiment surrounding AMLX stock, leading to the bearish movement observed today.

28.03.2026 - AMLX Stock was down 5.1%

• An increased price target for AMLX was influenced by a reduced expense forecast, potentially boosting investor confidence initially.
• However, concerns arose over the reduced compensation of the Co-CEO and Director in 2025, prompting doubts about the company's financial well-being and future prospects, leading to the bearish market movement.
• The impending Q3 2025 earnings preview may also be contributing to investor unease and stock selling pressure.
• In summary, despite positive adjustments to the price target, the news about reduced executive compensation and the upcoming earnings report could have dampened optimism, resulting in the decline of AMLX stock.

06.03.2026 - AMLX Stock was up 5.1%

• AMLX experienced a notable 3.52% increase in share price on April 2nd, despite reporting $0 revenue in its recent earnings.
• The positive market response could be linked to the successful enrollment and dosing completion of its pivotal Phase 3 LUCIDITY trial, marking a significant achievement for the company.
• Investor confidence in the potential success of avexitide for post-bariatric hypoglycemia, demonstrated by the trial enrollment completion, likely influenced the bullish movement.
• Concerns about stock dilution after the shelf filing appear to have been outweighed by favorable developments in the company's clinical trials, prompting the upward trend in the stock price.

12.04.2026 - AMLX Stock was down 5.2%

• A Discounted Cash Flow (DCF) analysis suggests AMLX is significantly undervalued, but its Price-to-Book (P/B) ratio indicates overvaluation compared to industry peers.
• Despite positive developments like completing enrollment for a pivotal trial and initiating an Expanded Access Program, AMLX's stock is trading below consensus targets and fair value estimates, leading to a large valuation gap.
• Analysts have provided varied ratings on AMLX, reflecting differing outlooks on the company's stock performance.
• The overall bearish movement in the healthcare sector, as evidenced by other healthcare stocks experiencing significant decreases in the pre-market session, could have contributed to AMLX's downward trend today.

07.04.2026 - AMLX Stock was down 6.9%

• The decline in AMLX stock today could be linked to the anticipation of the company's first-quarter financial results, which are projected to show a per-share loss and no revenue. This financial performance may have disappointed investors.
• Furthermore, the market's reaction to the news about the upcoming Phase 3 LUCIDITY trial data for avexitide, crucial for the company's future valuation and cash position, may have added to the negative sentiment.
• Amylyx Pharmaceuticals' involvement in investor conferences could have also impacted market sentiment, as investors may be waiting for insights or updates from these events before making significant decisions regarding the stock.
• Overall, factors such as financial performance expectations, forthcoming trial data, and participation in investor conferences likely contributed to the bearish movement in AMLX stock today.

14.03.2026 - AMLX Stock was up 5.3%

• The bullish movement in AMLX stock could be attributed to the selection of AMX0318 as a new development candidate, indicating progress in the company's pipeline for treating neurodegenerative diseases.
• The upcoming presentation at the 25th Annual Needham Virtual Healthcare Conference might have generated positive investor sentiment, as it provides a platform for the company to showcase its innovative therapies and potential market opportunities.
• Despite the investigation into potential breaches of fiduciary duties by insiders, investors seem optimistic about the company's future prospects, possibly due to the focus on addressing diseases with high unmet needs and the positive market analysis reports.
• Overall, the combination of positive corporate developments, upcoming conference presentation, and market analysis highlighting growth potential could have fueled the bullish momentum in AMLX stock today.

10.03.2026 - AMLX Stock was down 5.1%

• The bearish movement in AMLX's stock price could be attributed to the ongoing investigation into potential breaches of fiduciary duties by the company's officers and directors. This uncertainty may have led to a lack of investor confidence in the stock.
• Additionally, despite the positive news of AMLX's participation in the 25th Annual Needham Virtual Healthcare Conference to showcase its development candidates, the market may have reacted negatively to the lack of concrete updates or significant announcements during the event.
• The insider trading activities disclosed in the SEC filings, including stock sales for tax obligations and gifts, might have also contributed to the downward pressure on AMLX's stock price as investors may interpret these actions as a lack of long-term confidence in the company's prospects.
• Overall, the combination of legal investigations, lack of significant updates from the healthcare conference, and insider trading activities could have collectively influenced the bearish market movement in AMLX today.

17.03.2026 - AMLX Stock was up 5.4%

• Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) received a "Moderate Buy" recommendation from brokerages, indicating positive sentiment towards the stock.
• The company reported quarterly earnings that slightly beat analyst estimates, contributing to the bullish movement in the stock.
• Insider transactions, such as recent sales by the CEO, and adjustments in holdings by institutional investors may have influenced market confidence in the company's future prospects, driving the bullish movement in the stock.